XTRAC is the only FDA-cleared, clinically proven excimer laser that gets skin clear of psoriasis—and it works fast, with many patients seeing significant improvement and long-lasting remissions. Because XTRAC delivers a highly targeted, therapeutic beam of UVB light only to areas of the skin affected by psoriasis, healthy skin surrounding the lesions stays that way.
XTRAC clears the symptoms, prolongs the remission and returns skin to a clinically healthy state in record time. All of which means XTRAC delivers consistently predictable results so patients experience more good days of living than bad.
*Results may vary, talk to your doctor about the right treatment protocol for you.
Side Effects/Risks: XTRAC has none of the drawbacks often associated with other psoriasis treatments-such as premature aging of healthy skin, skin thinning, resistance to medication, or potential negative systemic side effects. Some patients, however, experience a reaction similar to sunburn or blistering at the site of the treated area and in some cases, an increase in pigmentation may occur.
Because of the shielding effect of hair, traditional UVB lamp therapy is not very effective against scalp psoriasis. However, studies have reported success in treating it with the [XTRAC] 308 nm excimer laser which generates a targeted beam of UVB light.
XTRAC allows for simple manual separation of the hair, provides good visualization of the psoriasis and permits rapid treatment so that a whole scalp can often be treated in less than 15 minutes.
XTRAC treatments can minimize and, in many cases, even eliminate Vitligo depigmented patches. The XTRAC [308 nm] excimer laser delivers a targeted beam of UVB light and only the areas of skin affected by Vitiligo receive the laser energy.
Though the laser spot size measures only 18mm x 18mm, due to rapid exposure times, relatively large, discrete areas can be treated in just five to 10 minutes, which is much quicker than the duration of conventional phototherapy light sessions. And most importantly, XTRAC treatments achieve complete response rates faster in a higher proportion of patients.